Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Inclusion Criteria

• •History of breast cancer, stages I-III with pathology confirmed at MSKCC
• •Women who have completed all of their primary treatment (surgery, radiation therapy, adjuvant chemotherapy) with the exception of endocrine therapy and currently have no clinical evidence of disease.
• •Women who are currently on aromatase inhibitors for at least three months--either letrozole or anastrozole
• •Women with symptomatic urogenital atrophy: vaginal dryness, irritation, pruritus, dyspareunia, urinary frequency and/or urinary incontinence
• •Menopausal at study entry defined as:
• •* Bilateral salpingo-oophorectomy independent of age
• •* If natural menopause, age ≥ 50 with cessation of menses for at least 12 months
• •* If menopause induced by chemotherapy, age ≥ 50 with no menstrual period at least 12 months after chemotherapy finished
• •At least 18 years of age
• •Able to participate in the informed consent process
• •Gynecology examination within six months
• •Able to read/speak English